Psoriatic Arthritis – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key psoriatic arthritis patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.
Use the Extrapolated Worldwide Coverage dashboard to do the following:
- View 10-year forecasts of the total prevalent cases for all 171 countries, stratified by region and World Bank income status.
- Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
- Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
- Generate and export global heat maps of disease risk or patient population size.
The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the “Downloads” section. It is available for purchase by clients who subscribe to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact healthcare.support@clarivate.com.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
